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Abstract
Background: For the analysis of 6-thioguanine nucleotides 
(6-TGN) and 6-methylmercaptopurine ribonucleotides 
(6-MMPR), no external quality assessment scheme (EQAS) 
is currently available and no quality control samples can 
be made because of the absence of pure substances. An 
experimental design is tested to compare laboratory ana-
lytical results.
Methods: In this EQAS, participating laboratories were 
asked to select patient samples from their routine analysis 
and exchange these with a coupled laboratory. Because 
of large differences in results between laboratories, all 
standard operating procedures were reviewed, revealing 
that the origin of these differences could be in the method 
of hydrolysis and the preparation of calibrators. To inves-
tigate the contribution of the calibrators to these differ-
ences, one participating laboratory was asked to prepare 
a batch of calibrators to be shipped to the participating 
laboratories for analysis.
Results: Results for 6-TGN differed more between labora-
tories, compared with results for 6-MMPR. For 6-TGN and 
6-MMPR 43% and 24% of the results, respectively, were 
out of the 80%–120% range. When correcting the results 
from the exchange of the patient samples with the results 
of the calibrators, the mean absolute difference for 6-TGN 
improved from 24.8% to 16.3% (p < 0.001), while the results 
for 6-MMPR worsened from 17.3% to 20.0% (p = 0.020).
Conclusions: This first EQAS for thiopurine drugs shows 
that there is a difference between laboratories in the 
analysis of 6-TGN, and to a lesser extent in the analysis 
of 6-MMPR. This difference for 6-TGN can partially be 
explained by the use of in-house-prepared calibrators that 
differ among the participants.
Keywords: external quality assessment scheme; harmoni-
zation; thiopurine drugs.
Introduction
Thiopurine drugs, azathioprine, 6-mercaptopurine and 
6-thioguanine (6-TG), are frequently used in the treatment 
of inflammatory bowel disease, such as Crohn’s disease 
and ulcerative colitis. Because of great interindividual 
pharmacokinetic differences, therapeutic drug monitoring 
is applied to measure 6-thioguanine nucleotides (6-TGN) 
and 6-methylmercaptopurine ribonucleotides (6-MMPR) 
[1]. The 6-TGN metabolite group consists of 6-thiogua-
nine monophosphate, -diphosphate and -triphosphate 
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and are related to the clinical efficacy and toxicity of the 
thiopurine drugs. The 6-MMPR metabolites are 6-methyl-
thioinosine monophoshate, -diphosphate and -triphos-
phate and are related to liver and bone marrow toxicity 
[2]. Since 6-TGN and 6-MMPR metabolites are stored in the 
red blood cell (RBC) their concentrations are expressed as 
pmol/8 × 108 RBC.
According to the international standard ISO/IEC 
15189:2012 [3] with requirements for quality and competence 
for medical laboratories, each laboratory should participate 
in interlaboratory comparisons or proficiency testing for all 
analytes they routinely measure. Since no external quality 
assessment scheme (EQAS) for thiopurine drugs was avail-
able in The Netherlands, the Section Therapeutic Drug 
Monitoring and Clinical Toxicology (KKGT) of the Dutch 
Foundation for Quality Assessment in Medical Laborato-
ries has started a pilot EQAS for thiopurine drugs. This pilot 
EQAS is part of the philosophy of Calibration 2.000 [4].
Because ISO/IEC 17043:2010 [5] states that material 
used in EQAS “should match in terms of matrix, meas-
urand and concentrations, as closely as practicable, the 
type of items or materials encountered in routine testing 
or calibration”, no centrally fabricated sample could be 
prepared due to the unavailability of pure substances of 
the 6-TGN and 6-MMPR metabolites. In addition, patients 
using purine drugs could be asked to do a blood donation 
for production of EQAS samples, but the availability of a 
sufficient number of donors may be problematic. There-
fore, in this pilot EQAS, an experimental design was tested 
in which patient samples were exchanged between pairs 
of laboratories instead of a centrally fabricated sample 
which was sent to all participants.
Materials and methods
Exchange of patient samples
In each EQAS round, each participating laboratory was coupled to 
one of the other laboratories, creating different laboratory couples in 
different rounds (e.g. in the first round laboratory 1 is coupled to lab-
oratory 2, in the second round laboratory 1 is coupled to laboratory 
3). Each laboratory was asked to select three patient samples from 
their routine thiopurine samples and to exchange these samples with 
the coupled laboratory. The laboratory which received the patient 
sample is defined as the first laboratory, the laboratory that received 
the samples from the first laboratory for the exchange is defined as 
the second laboratory. In the seven rounds a total of 11 laboratories 
participated.
The 6-TGN and 6-MMPR metabolites are unstable in fresh patient 
samples stored in the refrigerator, but more stable when RBCs are iso-
lated before storage in the freezer [6]. Therefore, the laboratories which 
obtained the patient samples were instructed to perform the RBC 
isolation and count, divide the sample in two aliquots, subsequently 
freeze the samples and to send one of the frozen samples to the cou-
pled laboratory. With the shipment of the samples, the first laboratory 
reported the measured RBC counts of the samples to the second labora-
tory, so that the second laboratory could express the measured 6-TGN 
and 6-MMPR concentrations in the regular unit pmol/8 × 108 RBC. Both 
laboratories performed the deproteinization and hydrolysis steps on 
the frozen sample and analyzed the 6-TGN and 6-MMPR metabolite 
concentrations according to their validated methods.
The exchange of these patient samples was coordinated by 
the EQAS provider KKGT. Before each EQAS round, laboratory cou-
ples were formed, and each laboratory was assigned three sample 
numbers for numbering of the patient samples. Laboratories were 
provided with instructions and the materials needed for the patient 
sample exchange, such as tubes, labels with the assigned sample 
numbers, absorption material, blisters and a label with the address 
of the coupled laboratory. Upon participation, each laboratory 
received an insulating Neopor box and a −30 °C temperature shell 
(inside which the patient samples were placed) for distribution of the 
samples.
Each laboratory reported the 6-TGN and 6-MMPR results of the 
patient samples to the EQAS provider, together with information 
about whether the samples were received frozen and the dates of 
receipt of the samples in the first and second laboratory, RBC iso-
lation and count, 6-TGN and 6-MMPR analysis and shipment. The 
EQAS provider made a report of the aggregated results.
Participants and measurement methods
All participants reported to use the Dervieux method [7].
Review methods of analysis
Due to large differences in the analytical results between laborato-
ries in the first two rounds, all standard operating procedures were 
retrieved from the participants for a systematic review. The  analytical 
method used may have great impact on the analytical results. For 
instance Shipkova et al. [8] reported 1.4–2.6-fold higher 6-TGN results 
for patient samples analyzed with the Dervieux method [7] compared 
to the Lennard method [9]. This difference could be the result of (a) 
differences in the duration of hydrolysis, (b) the concentration and 
type of acid used for hydrolysis and/or (c) the dithiothreitol (DTT) 
concentration, which is used for the protection of oxidation of the 
thiol groups.
Therefore, the first focus in our review of the standard operation 
procedures was the process of hydrolysis. The second focus of our 
review was the preparation of the calibrators, because a constant bias 
was observed between the results of some laboratories possibly attrib-
utable to a difference in calibration, and because calibrators are not 
commercially available but instead are prepared in each laboratory.
Calibrators
Because of differences observed in the standard operating proce-
dures describing the preparation of calibrators, calibrators for 6-TGN 
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and 6-MMPR analysis, which were prepared according to the stand-
ard operating procedure of one of the participating laboratories, were 
sent to all participants in the third round of 2015. The participating 
laboratories were asked to analyze these calibrators in a patient sam-
ple run and to calculate the concentration of the received calibrators 
on their own calibrators.
Since no pure substances for 6-TGN and 6-MMPR metabolites 
were available, and the metabolites are hydrolyzed to 6-TG and 
6-methylmercaptopurine (6-MMP) in the analytical process, the pure 
substances 6-TG and 6-MMP were used for the preparation of the cali-
brators.
The calibrators were produced as follows: blood was drawn 
from a healthy volunteer, not using any of the thiopurine drugs, in 
lithium-heparin tubes. The samples were washed according to the 
standard operating procedure for patient samples containing 6-TGN 
and 6-MMPR, an RBC count was performed and if necessary the RBC 
concentration was adjusted to 4.0–4.5 × 1012 RBC/L with phosphate 
buffered saline. The matrix was then spiked with 6-TG purchased 
from Sigma (Saint Louis, MO, USA) and 6-MMP purchased from TRC 
(Toronto, Ontario, Canada). A 6-TG stock solution was prepared by 
dissolving 11.96 mg of 6-TG in 4.0 mL 0.1 mol/L sodium hydrochloride 
and diluted with water for injections to 50.0 mL. A volume of 2.0 mL 
of this stock solution was diluted to 20.0 mL with distilled water, cre-
ating a 6-TG stock solution of 143 μmol/L. 10.00  mg of 6-MMP was 
dissolved in 4.0  mL 0.1  mol/L sodium hydrochloride, after which 
10.0  mL 0.1  mol/L hydrochloric acid was added. This solution was 
diluted with distilled water to 50.0 mL, creating a 6-MMP stock solu-
tion of 1478 μmol/L. All chemicals were commercially purchased and 
of reagent grade.
Three aliquots of washed blank lithium-heparin blood samples 
of 20 mL were spiked with 0.30, 0.45 and 0.70 mL 6-TG stock solution 
and 0.30, 0.40 and 0.70 mL 6-MMP stock solution, creating three lev-
els of 6-TG and 6-MMP concentrations (Table 1). Samples were frozen 
and shipped in temperature shells to the participants.
Data analysis
With this design for external quality control, no reference value can 
be assigned to the exchanged patient samples, therefore the reported 
results cannot be related to a true value. The reported results can 
only be related to each other, and no judgment about good or bad 
performance can be made from the results in this EQAS. Results of 
the patient sample exchange were expressed as the result of the sec-
ond laboratory as the percentage of the result of the first laboratory.
A 20% deviation (80%–120%) was chosen to be acceptable, 
based the EMA guideline on bioanalytical method validation [10] 
and previous set limits around true values in EQAS [11–13]. The EMA 
guideline sets a limit of 15% for accuracy for the entire concentration 
range but a 20% limit for the lower limit of quantification (LLOQ). In 
this EQAS, 20% deviation was chosen because preferably one devia-
tion limit is applied, and the most mild one was selected.
Results
In 2014, three rounds of patient sample exchanges were 
organized. Seven laboratories participated in the first 
round; therefore two laboratory couples were formed and 
the remaining three laboratories exchanged samples in a 
triangular approach. In both the second and third rounds 
of 2014, eight laboratories participated. In 2015, four 
rounds were organized with 10 participating laboratories 
in the first three rounds, and 11 participants in the fourth 
round. In the first seven rounds, a total of 192 patient 
samples were exchanged. Out of 192 patient samples, 
147 were received in a frozen state by the second labora-
tory and included in the analysis.
Patient sample exchange
The 6-TGN and 6-MMP results of the first seven rounds of 
patient sample exchange are depicted in Figures 1 and 2. 
A line of identity is displayed to obtain a clear picture of 
the correlation between the result of the first laboratory 
which obtained the patient sample, and the correspond-
ing result of the second laboratory. Two dotted lines are 
displayed to indicate the 20% deviation ranges from the 
line of identity.
Large differences existed between laboratories for 
the 6-TGN results. For 6-TGN and 6-MMP of four and 
23  samples, respectively, at least one of the values was 
reported as smaller than LLOQ or larger than upper 
limit of quantification, and therefore, no percentage 
could be  calculated. These results were discarded from 
Table 1: Calibrator 6-TG and 6-MMP concentrations.
Level 1, μmol/L Level 2, μmol/L Level 3, μmol/L
6-TG 2.15 3.22 5.01
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Figure 1: 6-TGN results from seven rounds of patient sample 
exchange between laboratories.
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the analysis. For one sample, the results for 6-TGN and 
6-MMP reported by the second laboratory were, respec-
tively, 266 and 294 times higher, and both were identified 
as a visual outlier.
For 6-TGN, 61/142 (43%) paired results were outside 
the 80%–120% ranges. In contrast, 6-MMPR results were 
more comparable: 30 (24%) of 123 paired results were 
outside the 80%–120% ranges.
Review method of analysis
The review of the analytical methods used revealed 
several differences between laboratories. Main differences 
observed (among other small differences) were (1) the 
amount of acid used in the denaturation of the proteins in 
the patient RBC, (2) the concentration and volume of the 
DTT solution added to patient sera, and (3) the prepara-
tion of the calibrators. The main differences between labo-
ratories are described in Table 2.
Calibrators
The centrally prepared calibrators were sent to 10 labora-
tories. One laboratory did not analyze the samples and one 
laboratory received the samples after 3 days, resulting in 
Table 2: Main differences in amount of acid, DTT concentration and calibrator matrix and preparation in the analysis of 6-TGN and 6-MMPR.
Laboratory   Acid   DTT conc., mM  Calibrator matrix   Calibrator preparation
1   11% Perchloric 
acid 70%
  72  Left over lithium-heparin blood 
samples used for other analysis 
(without 6-TGN and 6-MMPR)
  Centrifuge, discard plasma and 
buffy coat, store in freezer and 
spike with 6-TG and 6-MMP 
before analysis
2   8% Perchloric 
acid 70%
  50  Fresh, blanc lithium-heparin blood 
samples from healthy volunteers
  Wash according to the SOP for 
patient samples, store in freezer 
and spike with 6-TG and 6-MMP 
before analysis
3   12% Perchloric 
acid 70%
  60  Erythrocytes in SAGM (saline, adenine, 
glucose, mannitol), purchased from 
the national blood bank
  Dilute in a 1:1 ratio with PBS, 
spike with 6-TG and 6-MMP and 
store in freezer
4   14% Perchloric 
acid 70%
  60  Fresh, blanc lithium-heparin blood 
samples from healthy volunteers
  Wash according to the SOP for 
patient samples, spike with 6-TG 
and 6-MMP and store in freezer
5   13% Perchloric 
acid 70%
  66  Erythrocytes in SAGM, purchased from 
the national blood bank
  Dilute in a 1:1 ratio with PBS, 
spike with 6-TG and 6-MMP and 
store in freezer
6   12% Perchloric 
acid 70%
  60  Fresh, blanc lithium-heparin blood 
samples from healthy volunteers
  Wash according to the SOP for 
patient samples, store in freezer 
and spike with 6-TG and 6-MMP 
before analysis
7   12% Perchloric 
acid 70%
  60  Erythrocytes in SAGM, purchased from 
the national blood bank
  Dilute in a 1:1 ratio with PBS, 
spike with 6-TG and 6-MMP and 
store in freezer
8   13% Perchloric 
acid 70%
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Figure 2: 6-MMPR results from seven rounds of patient sample 
exchange between laboratories.
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thawed samples and degraded 6-TG and 6-MMP. Results of 
the remaining eight laboratories are depicted in Figure 3. 
The results are comparable to the results which were 
observed in the exchange of patient sera; results for 6-TG 
differ greatly among laboratories while 6-MMP results are 
more comparable between laboratories.
The results from the former analysis of the calibrators 
indicate that the use of different calibrators could con-
tribute to the observed differences in patient sera results. 
To test this hypothesis, the results of the calibrators were 
used to correct the patient sera results to assess the contri-
bution of the use of different calibrators to the differences 
in results for 6-TGN and 6-MMPR between laboratories. 
Because two laboratories did not report results for the cali-
brators and one laboratory received thawed and degraded 
samples, 47 6-TGN and 43 6-MMPR results could not be 
corrected for the results of the calibrators.
The difference between the results of the first 
and second laboratory was expressed as the absolute 
 percentage of the result of the first laboratory. The abso-
lute percentages were compared before and after cor-
rection for the calibrator results. The results for 6-TG 
improved and the results for 6-MMP worsened after cor-
rection (Table 3).
Comparison of the mean within-laboratory variances 
with the overall variances showed significant differences 
for both 6-TG (0.017 vs. 1.995, p < 0.001) and 6-MMP (0.527 
vs. 30.14, p < 0.001), indicating that the overall vari-
ances are mainly determined by the between-laboratory 
variances.
Discussion
The results of this first EQAS for the analysis of thiopurine 
drugs show that there is a large interlaboratory variation 
in the analytical results for 6-TGN. For 6-MMPR, the results 
between the laboratories differ less. For the analysis of 
6-TGN, the use of in-house-prepared calibrators among 
the laboratories seems to contribute for approximately 
34% of this difference. Because the overall variances for 
both 6-TGN and 6-MMP in the calibrator samples are pri-
marily determined by the between-laboratory variances, 
our hypothesis was that the differences seen in the results 
of the patient samples would diminish. This effect was 
only seen in the 6-TGN results, possibly due to non-com-
mutability of the calibrator for the 6-MMPR analysis or due 



















































Figure 3: Results for 6-TG and 6-MMP in three calibrator samples.
Table 3: Mean absolute differences (%) for 6-TG and 6-MMP in patient samples before and after correction for the calibrator results.
  n   Before correction   After correction   Difference   95% CI   p-Value
6-TG   95   24.8   16.3   8.5   4.4–12.8   <0.001
6-MMP   80   17.3   20.0   −2.7   −5.0 to −0.4   0.020
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despite the fact that the participants claim to use the same 
method and apply the same therapeutic range.
A previous study by Shipkova et al. [8] showed that 
6-TGN results were different between two methods of 
analysis, due to the differences in the duration of hydroly-
sis, the concentration and type of acid used for hydrolysis 
and/or the DTT concentration. The participating labo-
ratories in this study all claimed to apply the Dervieux 
method, but during the review of the used analytical 
methods, deviations from the publication of Dervieux [7] 
were seen in the amount of acid and DTT used. These dif-
ferences in the amount of acid and DTT used could be a 
(partial) explanation for the residual difference after cor-
rection for the calibrator.
Due to the use of patient samples in this EQAS and the 
lack of a reference method and certified reference mate-
rial, no statement can be made about the accuracy of the 
results of the participating laboratories, only a statement 
about the results of the laboratories compared to each 
other can be made. This is a weak point of the study, but 
inevitable since there is no certified reference material 
available. On the other hand, this study is able to demo-
nstrate the differences between laboratories, and it dem-
onstrates the urgent need for harmonization.
Due to stability reasons and the RBC count, a part 
of the pre-treatment of the samples could only be per-
formed by the first laboratory before the frozen samples 
could be send to the second laboratory. This is not ideal 
in an EQAS since preferably the entire analytical process 
is included, but inevitable in this design and the charac-
teristics of the analytes. The use of calibrators as EQAS 
samples was an improvement compared to the exchange 
of patient samples because all laboratories received the 
same sample and a more solid comparison between labo-
ratory methods could be made, but the disadvantage of 
the lack of pre-treatment remains.
A disadvantage of both approaches is the instability 
of the 6-TGN and 6-MMPR metabolites and the shipment 
of the sample. The amount of variability introduced by the 
shipment is unknown. The extent of this uncertainty is 
reduced by only including samples which arrived frozen 
in the second laboratory. The shipment of the sample is on 
the other hand a true comparison with an actual patient 
sample because these are often also shipped to a labora-
tory for analysis.
An advantage of the use of the calibrators is that 
the differences between laboratories can be primarily 
assigned to the analytical process. In the future, a further 
improvement of this EQAS may be pursued by sending 
pooled patient material or single patient donations to the 
participating laboratories.
Even though no true comparison between labora-
tories can be made for the analysis of thiopurine drugs, 
this exchange and analysis of patient samples and cali-
brators is a first report of the differences between labora-
tory results for thiopurine metabolites. These differences 
may have a negative impact on patient care when patients 
switch between different health-care providers and dose 
adjustments are be made according to the results of differ-
ent laboratories.
Conclusions
This first EQAS for the analysis of thiopurine drugs 
shows that there is a large difference between analytical 
6-TGN results coming from different laboratories whereas 
6-MMPR results do not seem to differ in a clinically rel-
evant way. This difference for 6-TGN may partially be 
explained by the use of in-house-prepared calibrators that 
differ among the different laboratories. It is recommend-
able to harmonize the calibrators as a first step to reduce 
between-laboratory variation. More research is needed 
to determine which other factors contribute to the differ-
ences between laboratories in order to further reduce the 
between-laboratory variation.
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